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Systems genetics identiﬁes Sestrin 3 as a
regulator of a proconvulsant gene network in
human epileptic hippocampus
Michael R. Johnson1,y, Jacques Behmoaras2,*, Leonardo Bottolo3,*, Michelle L. Krishnan4,*, Katharina Pernhorst5,*,
Paola L. Meza Santoscoy6,*, Tiziana Rossetti7, Doug Speed8, Prashant K. Srivastava1,7, Marc Chadeau-Hyam9, Nabil Hajji10,
Aleksandra Dabrowska10, Maxime Rotival7, Banafsheh Razzaghi7, Stjepana Kovac11, Klaus Wanisch11, Federico W. Grillo7,
Anna Slaviero7, Sarah R. Langley1,7, Kirill Shkura1,7, Paolo Roncon12,13, Tisham De7, Manuel Mattheisen14,15,16,
Pitt Niehusmann5, Terence J. O’Brien17, Slave Petrovski18, Marec von Lehe19, Per Hoffmann20,21, Johan Eriksson22,23,24,
Alison J. Coffey25, Sven Cichon20,21, Matthew Walker11, Michele Simonato12,13,26, Be´ne´dicte Danis27, Manuela Mazzuferi27,
Patrik Foerch27, Susanne Schoch5,28, Vincenzo De Paola7, Rafal M. Kaminski27, Vincent T. Cunliffe6, Albert J. Becker5,y &
Enrico Petretto7,29,y
Gene-regulatory network analysis is a powerful approach to elucidate the molecular processes and
pathways underlying complex disease. Here we employ systems genetics approaches to characterize the
genetic regulation of pathophysiological pathways in human temporal lobe epilepsy (TLE). Using
surgically acquired hippocampi from 129 TLE patients, we identify a gene-regulatory network genetically
associated with epilepsy that contains a specialized, highly expressed transcriptional module encoding
proconvulsive cytokines and Toll-like receptor signalling genes. RNA sequencing analysis in a mouse
model of TLE using 100 epileptic and 100 control hippocampi shows the proconvulsive module is
preserved across-species, speciﬁc to the epileptic hippocampus and upregulated in chronic epilepsy. In
the TLE patients, we map the trans-acting genetic control of this proconvulsive module to Sestrin 3
(SESN3), and demonstrate that SESN3 positively regulates the module in macrophages, microglia and
neurons. Morpholino-mediated Sesn3 knockdown in zebraﬁsh conﬁrms the regulation of the
transcriptional module, and attenuates chemically induced behavioural seizures in vivo.
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E
pilepsy is a serious neurological disorder affecting about 1%
of the world’s population. Recently, a growing body of
experimental and clinical data has implicated Toll-like
receptor (TLR) signalling1 and release of proconvulsant
inﬂammatory molecules (that is, interleukin (IL)-1b) in both
seizure generation and epileptogenesis2,3. However, the
pathogenetic mechanisms linking these inﬂammatory processes
with the development (and recurrence) of epileptic seizures in
humans are unclear. Despite high heritability of epilepsy4–6, both
genome-wide association studies (GWAS) and exome sequencing
approaches have so far provided limited insights into the genetic
regulatory mechanisms underlying inﬂammatory pathways in
epilepsy aetiology7–11, and traditional single-variant association
approaches are likely to be underpowered to detect complex gene
network interactions that underlie disease susceptibility12. As the
molecular processes driving complex disease usually affect sets of
genes acting in concert, one alternative strategy is to use systems-
level approaches to investigate transcriptional networks and
pathways within pathologically relevant cells and tissues13,14.
Integrated analysis of transcriptional networks with genetic
susceptibility data and phenotypic information allows speciﬁc
transcriptional programmes to be connected to disease states, and
thereby can identify disease pathways and their genetic regulators
as new targets for therapeutic intervention15.
Almost uniquely among disorders of the human brain, epilepsy
surgery offers opportunities for gene expression proﬁling in
ante-mortem brain tissue from pathophysiologically relevant
brain structures such as the hippocampus16. This allows direct
investigation of transcriptional programmes in brain tissue from
living epilepsy patients. In this study, we integrate unsupervised
network analysis of global gene expression in the hippocampi
of patients with temporal lobe epilepsy (TLE) with GWAS
data in a systems genetics approach17. We uncover pathways
and transcriptional programmes associated with epilepsy that
are conserved in mouse epileptic hippocampus, including
a proconvulsant gene network encoding IL-1b3 and
TLR-signalling genes1 previously implicated in epilepsy. Using
genome-wide Bayesian expression QTL mapping18, we probe the
genome for key genetic regulators of the network in human brain.
We pinpoint an unexpected gene, Sestrin 3 (SESN3) whose
protein product controls the intracellular response to reactive
oxygen species19–22, as a trans-acting genetic regulator of
the proconvulsant gene network in the human epileptic
hippocampus. We carry out validation experiments in
independent in vitro and in vivo systems, which conﬁrm the
genetic regulation of the proconvulsant transcriptional
programme in epilepsy by Sestrin 3, therefore providing a ﬁrst
evidence of a function for SESN3 in disorders of the human brain.
Results
Identiﬁcation of a gene network associated with epilepsy. We
ﬁrst assessed the degree of variation in gene expression between
hippocampal subﬁelds in TLE patients with hippocampal
sclerosis, and compared this with the total variation in gene
expression measured both across subjects and between subﬁelds
(Supplementary Fig. 1). We found higher variability in gene
expression across TLE subjects than between the hippocampal
subﬁelds alone, suggesting that variation in whole hippocampus
expression can be used to infer co-expression networks in the
hippocampus of TLE patients (Supplementary Fig. 1). After
excluding subjects with incomplete clinical data or non-
hippocampal sclerosis pathology, whole-genome expression
proﬁles in surgically resected hippocampi from 129 TLE patients
(median age at surgery 35 years, range 1–64 years, male/female
ratio of 1.2:1; Supplementary Table 1) were available for gene
co-expression network analysis.
We then investigated whether the transcriptome in the
hippocampus of these 129 TLE patients is organized into discrete
gene co-expression networks, and if these have functional
implications for susceptibility to epilepsy. Gene co-expression
networks were reconstructed genome wide using Graphical
Gaussian Models (GGMs)23, which identiﬁed a large co-
expression network comprising 442 annotated genes (false
discovery rate (FDR)o5%, Fig. 1a and Supplementary Data 1).
To investigate whether the protein products of the TLE-
hippocampus derived transcriptional network (TLE-network)
genes have a shared function at the protein level, we used the
DAPPLE algorithm24. This method interrogates high-conﬁdence
protein–protein interactions to assess the physical connections
among proteins encoded by the genes in the network.
Genes comprising the TLE-network were found to have
increased protein–protein interconnectivity as compared with
random protein–protein interaction networks (P¼ 9.9 10 5,
Supplementary Fig. 2). This provides evidence that proteins
encoded by the co-expressed genes in the TLE-network interact
physically, supporting the validity of the gene network
topography.
As gene expression may vary both as a cause and a
consequence of disease, we investigated the causal relationship
between the TLE-network and epilepsy by integration with
genetic susceptibility data. Here, DNA variation was used to infer
causal relationships between the network and epilepsy by
assessing whether the network as a whole was genetically
associated with epilepsy. To this aim, we used focal epilepsy
GWAS data6,25 from a separate cohort of 1,429 cases (consisting
mainly of patients with TLE) and 7,358 healthy controls.
Although no single-nucleotide polymorphism (SNP) achieved
genome-wide signiﬁcance in the epilepsy GWAS (Supplementary
Fig. 3), we found that the TLE-network as a whole was highly
enriched for genetic associations to focal epilepsy compared with
genes not in the network (P¼ 2 10 7; Fig. 1a and
Supplementary Table 2). These integrated analyses of co-
expression network and genetic susceptibility data from a focal
epilepsy GWAS provide independent evidence to support the
causal involvement of the TLE-network in epilepsy aetiology.
Conservation and functional specialization of the network. The
TLE-network was signiﬁcantly enriched for genes belonging to
several biological pathways involving cell-to-extracellular matrix
adhesion including ‘extracellular matrix–receptor interaction’
(P¼ 3.9 10 5), ‘focal adhesion’ (P¼ 1.4 10 4) and inﬂam-
mation, such as the ‘cytokine–cytokine receptor interaction’
(P¼ 2.4 10 5) and ‘TLR signalling’ (P¼ 3.9 10 5; Fig. 1b).
The observation that the TLE-network was enriched for multiple
pathways led us to investigate whether the network contained
functionally homogenous transcriptional modules (that is,
sub-networks of highly correlated genes) with implications for
epilepsy aetiology. Using unsupervised agglomerate clustering
approaches (see Supplementary Methods), we identiﬁed
two transcriptional modules comprising 69 (Module-1) and
54 (Module-2) unique genes, respectively (Fig. 1c and
Supplementary Data 1). Module-1 was speciﬁcally enriched for
gene ontology categories related to inﬂammatory mechanisms,
whereas Module-2 was enriched for cell-to-extracellular matrix
adhesion processes (Fig. 1d and Supplementary Table 3), indi-
cating functional sub-specialization within the larger TLE-
network. We observed that Module-1 genes were signiﬁcantly
upregulated as compared with genes in the larger TLE-network,
Module-2, or with respect to all other genes proﬁled in the hip-
pocampus of TLE patients (Fig. 1e). This increased hippocampal
expression of Module-1 genes in TLE patients was not observed
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in separate gene expression data sets from the hippocampus
of healthy subjects (that is, individuals clinically classiﬁed as
neurologically normal; Supplementary Fig. 4). Notably,
Module-1 was markedly enriched for highly expressed inﬂam-
matory cytokines (16-fold enrichment, P¼ 6.6 10 13) many of
which belong to the IL-1 signalling cascade (IL-1b, IL-1RN, IL-1a,
TNFa) and the TLR-signalling pathway (11-fold enrichment,
P¼ 1.4 10 6), previously implicated in epileptogenesis1
and brain inﬂammation2,3 (Supplementary Fig. 5). Taken
together, these data indicate the presence of a coordinated
transcriptional programme (Module-1), encompassing TLR
activation and release of proinﬂammatory cytokines (including
IL-1b), in chronic human epileptic hippocampus as previously
hypothesized3,26.
We then investigated whether the TLE-network and Module-1
genes, in particular, were conserved across-species and to this aim
we carried out high-throughput sequencing of mRNA (RNA-Seq)
in whole hippocampus from 100 epileptic (pilocarpine model)27
and 100 control naı¨ve mice (full details of this model are reported
in the Supplementary Methods). We employed GGMs to
assess the co-expression relationships between the 371 mouse
orthologues of the human TLE-network genes, and found that
312 genes (84%) had signiﬁcant co-expression (FDRo5%) with
at least another network gene in mouse epileptic hippocampus
(Fig. 2a). The conserved TLE-network genes formed 1,119
signiﬁcant partial correlations in mouse epileptic hippocampus,
which is signiﬁcantly higher than expected by chance (P¼ 0.001
by 10,000 bootstrap permutations; Fig. 2b). In contrast, only 615
signiﬁcant partial correlations between the same 312 genes were
detected in healthy hippocampus (P¼ 0.659 by 10,000 bootstrap
permutations), suggesting that the TLE-network is speciﬁcally
conserved in the epileptic mouse hippocampus (Fig. 2b). In
keeping with the high expression of proinﬂammatory genes
observed in the hippocampus of TLE patients (Supplementary
Fig. 5), the mouse orthologues of Module-1 genes that were
signiﬁcantly upregulated in epileptic hippocampus were enriched
for TLR-signalling and cytokines (gene set enrichment analysis28,
P¼ 9.03 10 4, Fig. 2c). These comparative genomics analyses
revealed that, to a large extent, the hippocampal TLE-network
is conserved across-species, and conﬁrm that genes for
TLR signalling and proinﬂammatory cytokines within the
TLE-network are upregulated in chronic epileptic hippocampus.
SESN3 is a genetic regulator of the proinﬂammatory network.
We set out to identify genetic variants that regulate the gene co-
expression modules (that is, regulatory ‘hotspots’) by employing
genome-wide Bayesian expression QTL mapping approaches18,29.
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Figure 2 | TLE-network conservation in mouse epileptic hippocampus. (a) Human TLE-network genes that are conserved and co-expressed (84%) in the
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To this aim, we have developed a multi-step strategy to identify
SNPs that regulate the expression of a transcriptional module (or
network) as a whole. As ﬁrst step, we summarize the expression
of the genes in each module using principal component (PC)
analysis and detect regulatory ‘hotspots’ using a Bayesian
regression model at the genome-wide level29. This analysis
prioritizes genomic regions associated with variation in mRNA
expression of the genes in each module. As a second step, to
reﬁne the genetic mapping results, we regress jointly the mRNA
levels of module genes to all SNPs within the regulatory locus
identiﬁed in the ﬁrst step18. Given the functional specialization
within the large TLE-network (Fig. 1d), we investigated the
genetic regulation of both Module-1 and Module-2, by analysing
527,684 genome-wide SNPs in the TLE patient cohort. In the ﬁrst
step, we identiﬁed a single locus on chromosome 11q21 centred
on SNP rs10501829, which was signiﬁcantly associated with the
ﬁrst PC of Module-1 expression (FDRo5%; Fig. 3a). Module-2
showed no signiﬁcant genome-wide associations (Supplementary
Fig. 6). In the second step, we investigated in detail the locus on
chromosome 11q21 regulating Module-1 and carried out joint
mRNA levels-SNPs analysis of all genes in Module-1 and all SNPs
genotyped within a 1-Mbp region centred on SNP rs10501829.
This analysis identiﬁed three additional SNPs (rs530190,
rs7107661 and rs6483435) in the Best Model Visited (that is,
the best combination of SNPs predicting mRNA level of module
genes, see Supplementary Methods) that were associated with the
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Figure 3 | SESN3 is a trans-acting genetic regulator of Module-1 in epileptic hippocampus. (a) Genome-wide mapping of the genetic regulation of
Module-1. For each autosome (horizontal axis), the strength of evidence for each SNP (ﬁlled dot) being a regulatory locus for the ﬁrst PC of Module-1
expression is measured by the log10(Bayes factor) (vertical axis). The Bayes factor quantiﬁes evidence in favour of genetic regulation versus no genetic
control of module expression, and is reported as a ratio between the strengths of these models. At 5% FDR (that is, log10(Bayes factor)46, dashed line),
SNP rs10501829 (11q21, highlighted in red) was signiﬁcantly correlated with Module-1 expression. (b) Joint mRNA levels and SNPs analysis within the
1-Mbp region centred on SNP rs10501829, comprising 178 SNPs genotyped in the TLE patient cohort. We carried out multivariate Bayesian regression
modelling18 of all Module-1 probes (n¼80) and all SNPs (n¼ 178) to identify the most informative SNPs in the region predicting Module-1 expression. For
each SNP, we report the proportion of associated genes in Module-1 (vertical axes): four SNPs (rs10501829, rs530190, rs7107661 and rs6483435) that are
individually associated with 58–74% of Module-1 genes are highlighted. The grey box indicates the boundaries of the associated regulatory region
(delimited by SNPs rs530190 and rs6483435), spanning 383 kb. (c) For each candidate gene at the 1-Mbp regulatory locus, we report the average Pearson
correlation (r;±s.e.m.) between the candidate gene’s expression and the expression of Module-1 genes (y axes) and its statistical signiﬁcance for deviation
from r¼0 (x axes). Two-tailed P-values are reported on a negative log scale and were calculated using one sample Wilcoxon Signed Rank test. Two genes
(ENDOD1 and MTMR2) were represented by two microarray probes and were analysed separately. (d) Association between increased Sesn3 mRNA
expression and upregulation of Module-1 genes in epileptic mouse hippocampus. For each gene, we report its log10(fold change) in epilepsy versus
control (y axes) and its correlation with Sesn3 mRNA expression (x axes). The 95% conﬁdence interval of the slope of the regression line is indicated.
TLR-signalling and cytokines genes are highlighted in blue.
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majority of genes of Module-1 (58–74% of Module-1 genes are
predicted by individual SNPs, Fig. 3b). The set of SNPs regulating
in trans the expression of Module-1 genes deﬁned the boundaries
of a minimal regulatory region spanning B383 kb (Fig. 3b).
The larger 1-Mbp region centred on SNP rs10501829
contained eight annotated protein-coding genes (Fig. 3b). To
further prioritize candidate genes, we carried out co-expression
analysis between each of these genes and all genes in Module-1,
and found that Sestrin 3 (SESN3) was, on average, most strongly
and positively correlated with Module-1 gene expression (P¼ 1.7
 10 13, Fig. 3c). The positive association between SESN3
and Module-1 gene expression remained signiﬁcant following
genome-wide correlation analysis in human hippocampus
(Po0.00001, Supplementary Fig. 7). In summary, SESN3 is the
only gene within the minimal regulatory region and, when
compared with all genes within a 1-Mbp window around SNP
rs10501829, showed the strongest correlation with Module-1 gene
expression. Similarly, in the epileptic mouse hippocampus,
we found that increased Sesn3 mRNA expression was also
signiﬁcantly associated with upregulation of Module-1 genes
(P¼ 5.4 10 6, Fig. 3d), therefore providing independent, cross-
species evidence supporting SESN3 as a positive regulator of
Module-1 genes in epileptic hippocampus.
Taken together, these data prioritize SESN3 as a candidate gene
for the trans-acting genetic regulation of Module-1. To test this
hypothesis, we ﬁrst carried out gene knockdown experiments
followed by transcriptional analysis of Module-1 genes by means
of RNA interference using short interfering RNA (siRNA).
Initially, we used murine bone marrow-derived macrophages
(BMDMs) and BV2 microglia cell line as an in vitro system as
Module-1 recapitulates the ATF3/AP1 transcriptional complex
and IL-1 signalling (Supplementary Fig. 8), known to be highly
expressed in lipopolysaccharide (LPS)-stimulated macrophages30.
Consistent with the positive correlation of Module-1 genes with
SESN3 mRNA expression (Fig. 3c,d and Supplementary Fig. 7),
we observed decreased expression of Module-1 genes after
siRNA-mediated knockdown of SESN3 in both LPS-stimulated
BMDMs and BV2 microglia cells (Fig. 4a,b). Similar results were
found in unstimulated BV2 microglial cells, suggesting that
SESN3 can modulate expression of proinﬂammatory genes
(for example, IL-1b, IL-1RN, IL-1a, TNFa) even in the
absence of a strong inﬂammatory stimulus (Fig. 4c). Within the
human brain we localized SESN3 expression to neurons by
immunohistochemistry (Fig. 4d), and found that it is highly
expressed in the hippocampus of TLE patients as compared with
hippocampus from control autopsy samples (Fig. 4e and
Supplementary Fig. 9). In keeping with this, we found increased
Sesn3 mRNA expression in the mouse hippocampus after
pilocarpine-induced status epilepticus (Supplementary Fig. 10),
suggesting an association between SESN3 gene expression and
epilepsy that is conserved across-species. We then tested whether
Module-1 genes are upregulated when SESN3 is overexpressed in
neurons. To address this aim, we used an integrating lentiviral
vector (LV) for gene overexpression in primary murine neurons
(see Supplementary Methods) and quantitative PCR analysis
showed that the relative levels of Sesn3 mRNA were markedly
increased in transduced neurons compared with the levels
observed in mock transduction (Fig. 4f). Consistent with the
observed positive correlation between increased Sesn3 expression
and Module-1 genes in the hippocampus (Fig. 3c,d), lentiviral-
mediated overexpression of Sesn3 resulted in signiﬁcant
upregulation of Module-1 genes in hippocampal neurons
(Fig. 4f). These in vitro experiments show that Sesn3 is capable
of regulating Module-1 gene expression in different cell types and
in particular of inducing upregulation of proinﬂammatory genes
in hippocampal neuronal cells. Our ﬁndings in primary neurons
are in keeping with previous data reporting the activity of several
inﬂammatory molecules in neuronal cells under pathological
conditions31, including IL-1b and its receptor32. Furthermore, the
upregulation of proinﬂammatory genes in neurons supports the
‘neurogenic inﬂammation’ hypothesis, wherein neurons are
proposed as triggers of innate and adaptive immune-cell
activation in the central nervous system (CNS; reviewed in
Xanthos and Sandkuhler33).
SESN3 regulates chemically induced behavioural seizures. The
in vitro data, combined with the positive association between
SESN3 and Module-1 gene expression in human and mouse
epileptic hippocampus, indicate that SESN3 is a positive regulator
of Module-1. We hypothesized that inhibiting SESN3 would
reduce the activity of genes in functional pathways enriched in
Module-1, including proconvulsant signalling molecules, and
thus by extension could have seizure-suppressing effects. To test
this hypothesis in vivo, we investigated the role of SESN3 in a
zebraﬁsh model of convulsant-induced seizures34,35. In this
model, exposure of 2- or 3-day-old zebraﬁsh larvae to the
convulsant agent pentylenetetrazole (PTZ) rapidly induces the
expression of synaptic activity-regulated genes in the CNS and
causes vigorous episodes of calcium ﬂux in muscle cells as well as
intense locomotor activity characteristic of epileptic seizures34,35.
This acute seizure model has been primarily used to investigate
the anti-/proconvulsant activity of compounds36 and for in vivo
drug discovery34. In particular, molecular and behavioural
Figure 4 | SESN3 regulates expression of Module-1 genes in macrophages, microglial cells and neurons. Effect of siRNA-mediated knockdown of Sesn3
as compared with control siRNA (siControl), showing signiﬁcant inhibition of Sesn3 mRNA expression and downregulation of Module-1 genes in murine
LPS-stimulated (1 h) BMDM (a) and BV2 microglial cells (b), as well as in unstimulated BV2 microglial cells (c). Five independent biological replicates were
used for BMDM experiments and at least three replicates in the BV2 microglia cells experiments. Data normalized to b-actin levels are shown as means
relative to control ±s.e.m. (d) SESN3 immunoﬂuorescence of human hippocampal slices from TLE patients: co-immunostainings with NeuN (green)
antibody showed that SESN3 (red) is localized in neurons. Scale bar, 100 mm. (e) Quantiﬁcation of SESN3 expression in human hippocampal tissue by
immunoﬂuorescence analysis. Maximum intensity projections of confocal z-stack images of immunohistochemical stainings with antibody against SESN3
were used. For determination of SESN3 cell ﬂuorescence as a measure of SESN3 expression level, SESN3-expressing cells in the CA2 region of the
hippocampus in both TLE patients samples (n¼ 7) and autopsy samples (n¼ 8) were measured using ImageJ software. Cell ﬂuorescence was assessed as
follows: integrated density—(area of selected cellmean ﬂuorescence of background readings). SESN3 total cell ﬂuorescence in TLE patients is
signiﬁcantly increased as compared with the SESN3 total cell ﬂuorescence in autopsy samples (two-tailed Mann–Whitney test, Po0.001). Fluorescence
intensity data are reported as means±s.e.m. (f) Effect of lentiviral-mediated Sesn3 overexpression on Module-1 genes in primary hippocampal neurons.
Left, relative levels of Sesn3 mRNA in transduced neurons (LV-CMV-Sesn3) compared with the levels in mock transduction (Mock). Right, relative mRNA
levels of Module-1 genes and a control gene not in the network (Hprt) in transduced neurons compared with levels in mock transduction. Data normalized
to Gapdh levels are shown as means relative to control±s.e.m. Four (Mock group) and twelve (LV-CMV-Sesn3 group) replicates were used in neuronal cell
experiments. Statistical signiﬁcance of the differences (P-value) between siSESN3 (or LV-CMV-Sesn3) and siControl (or Mock) was assessed by t-test
(two-tailed) and adjusting for unequal variances across different groups. *Po0.05; **Po0.01; ***Po0.001; ****Po0.0001; NS, not signiﬁcant (P40.05).
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phenotypes in the zebraﬁsh PTZ-induced seizure model have
been employed to identify compounds that attenuate seizure
activity37. We employed this model to correlate the locomotor
responses with gene network dynamics, that is, transcriptional
activation of the neuronal activity-regulated gene c-fos38 and an
additional subset of Module-1 genes in response to PTZ
treatment in Sesn3 morphant and control morphant larvae.
Sesn3 showed widespread expression in the brain of 3 and 4 days
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post fertilization (d.p.f.) zebraﬁsh larvae (Supplementary Fig. 11)
and, following PTZ treatment, we found that Sesn3 morphant
zebraﬁsh larvae exhibited signiﬁcantly reduced locomotor activity
as compared with control morphant larvae (Fig. 5a). To test the
speciﬁcity of the morpholino effect, we co-injected the Sesn3
morpholinos (Supplementary Fig. 12) along with synthetic Sesn3
mRNA, which cannot be targeted by either of the splice-blocking
morpholinos (see Supplementary Methods), and assessed whether
the Sesn3 mRNA could rescue the morphant phenotype. We
observed an almost complete rescue of the locomotor activity
phenotype (only 10% difference between uninjected larvae and
larvae co-injected with Sesn3 morpholinos and Sesn3 mRNA),
with no signiﬁcant differences in the locomotor activities between
the uninjected larvae and the larvae injected with synthetic Sesn3
mRNA alone (Fig. 5b).
To further conﬁrm Sesn3-dependent modiﬁcation of neuronal
response to PTZ, we measured transcriptional activation of the
neuronal activity-regulated gene c-fos, an important regulator
for cellular mechanisms mediating neuronal excitability and
survival38. Consistent with the behavioural assay (Fig. 5a), there
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Figure 5 | Sesn3 modulates PTZ-induced c-fos expression, locomotor convulsions and Module-1 genes in zebraﬁsh. (a) Left, Sesn3 promotes convulsive
locomotor response of zebraﬁsh larvae exposed to PTZ. Three days post fertilization (d.p.f.) zebraﬁsh larvae were incubated with and without 20mM PTZ
for 1 h and locomotor activity was monitored continuously. Larvae microinjected with Sesn3 morpholinos exhibited a sustained reduction in locomotor
activity throughout the period of PTZ incubation, in comparison with control morphant larvae. Both Sesn3 morphant and control morphant larvae (n¼ 12)
exhibited similarly low levels of locomotor activity in the absence of PTZ. Right, Sesn3 morpholinos reduced the cumulative locomotor activity of zebraﬁsh
exposed to 20mM PTZ (black columns) without appreciably affecting basal locomotor activity of larvae incubated in the absence of PTZ (white columns).
(b) Co-injecting Sesn3 morpholinos with synthetic Sesn3 mRNA showed that Sesn3 mRNA rescued the locomotor activity phenotype (total distance swam,
y axis). For each group, 16–18 larvae were analysed. Black bars, 1 h PTZ treatment (20mM). (c) Sesn3 morpholinos attenuate seizure-induced expression of
the synaptic activity-regulated gene c-fos. Left and central images, dorsal views of the brains of 3 d.p.f. control morphant (top) and Sesn3 morphant larvae
(bottom) maintained for 1 h in the absence and presence of 20mM PTZ, after which larvae were ﬁxed and analysed for c-fos expression by whole-mount
in situ hybridization. Red arrowheads: position of the transverse sections of the brains; scale bar, 200mm. Following PTZ treatment (20mM, 1 h),
quantitative PCR (qPCR) analysis revealed that Sesn3 morphant larvae exhibited signiﬁcantly lower mRNA expression of c-fos in the brain than control
morphant larvae (c, right panel). (d) PTZ-induced transcriptional response of Module-1 genes was signiﬁcantly lower in Sesn3morphants as compared with
uninjected larvae; six samples were used in the qPCR experiments (one sample¼ 15–20 pooled larvae). (e) Upregulation of Module-1 genes upon injection
of synthetic mRNA (1 ng) in zebraﬁsh embryos (n¼ 30) as compared with uninjected control embryos (n¼ 30). Total RNA was extracted 28 h post
fertilization and qPCR experiments were performed for the two pools of embryos using six technical replicates. Data reported as means±s.e.m. were
determined by the 2DDCt method and normalized to the housekeeping gene b-actin. P-values calculated by t-test (two-tailed) adjusting for unequal
variances across different groups. NS, not signiﬁcant (P40.05).
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was decreased expression of c-fos in the brain (mostly in forebrain
and midbrain) following PTZ exposure in Sesn3 morphant larvae
as compared with control morphant larvae (Fig. 5c and
Supplementary Fig. 12). As silencing of Sesn3 resulted in
downregulation of Module-1 genes in vitro (Fig. 4a–c), we
tested whether inhibiting Sesn3 could similarly reduce the activity
of Module-1 genes following PTZ exposure in vivo. We observed
signiﬁcant reduction in the PTZ-induced mRNA expression of
Module-1 genes in the Sesn3 morphant as compared with control
morphant larvae (Fig. 5d), and we also found that transient
overexpression of Sesn3 in zebraﬁsh larvae increased expression
of Module-1 genes independently of PTZ treatment (Fig. 5e).
Taken together, these data show that Sesn3 knockdown attenuates
both PTZ-induced locomotor convulsive behaviour and the
transcriptional responses of c-fos and Module-1 genes to
treatment with PTZ. These ﬁndings in the zebraﬁsh model
support the evidence from our studies of human and mouse
epileptic hippocampus and primary murine neurons that SESN3
positively regulates expression of proconvulsive molecules
(Module-1 genes).
Discussion
Deciphering the complex regulatory processes of pathophysiolo-
gical pathways in human brain remains a challenge due to the
inaccessibility of ante-mortem tissue but can have important
mechanistic and therapeutic implications39. In this study, we have
used surgical hippocampal tissue samples and employed systems
genetics approaches17 to investigate transcriptional networks for
epilepsy and their genetic regulation. We identiﬁed a large gene
co-expression network in the human epileptic hippocampus that
was conserved in mouse epileptic hippocampus and was enriched
for GWAS genetic signals of focal epilepsy. In keeping with
similar network-based studies of complex disease such as type-1
diabetes40 and autism spectrum disorder41,42, our approach
leverages the combined evidence from genetic susceptibility
variants across multiple genes15 to link the TLE-hippocampus
network with susceptibility to focal epilepsy. Within the TLE-
network, we identiﬁed a functionally coherent and coordinated
transcriptional programme (Module-1), which was overexpressed
in the hippocampus of TLE patients, and which encoded
epileptogenic IL-1 (refs 2,3,43) and TLR-signalling pathways1.
We conﬁrmed the upregulation TLR-signalling genes and
proinﬂammatory cytokines in chronic epilepsy by RNA-Seq
analysis in 200 mouse hippocampi. Preclinical studies in
experimental models of epilepsy have consistently shown that
individual proinﬂammatory cytokines such as IL-1b or tumor
necrosis factor (TNF)-a are overexpressed in brain areas of
seizure generation and propagation44. Therefore, targeting TLR
and IL-1 signalling has been proposed as a possible avenue for
therapeutic intervention in epilepsy and antiepileptogenesis1,3,
including reduction of acute seizures45 and drug-resistant chronic
epileptic activity46. The identiﬁcation of upstream genetic
regulators of these pathways in the human epileptic brain
might suggest opportunities for novel targets for disease
modiﬁcation. To investigate the genetic regulation of the
TLE-network and the proinﬂammatory module therein, we
employed Bayesian expression QTL mapping approaches18,
which identiﬁed SESN3 as a trans-acting genetic regulator of a
proinﬂammatory transcriptional programme in the epileptic
human hippocampus. The positive regulation of this network
by SESN3 was conﬁrmed in vitro across different cell types by
gene silencing (resulting in B50% reduction of Module-1 gene
expression) and overexpression experiments (resulting in
approximately two- to sevenfold activation of Module-1 genes,
Fig. 4), and in vivo using a zebraﬁsh model of chemically induced
seizures (Fig. 5e).
SESN3 is a member of the Sestrin family of proteins that have
been shown to decrease intracellular reactive oxygen species and
to confer resistance to oxidative stress19. Intrinsic antioxidant
defenses are important for neuronal longevity and the genes
that regulate these processes might well inﬂuence pathological
processes associated with oxidative damage in the brain, a
common feature of many neurodegenerative diseases including
epilepsy47,48. Therefore, we hypothesize that SESN3 might
regulate neuro-inﬂammatory molecules, previously implicated
in epilepsy1,33,43,49, through modulation of oxidative stress in
the brain.
Our systems genetics analysis in the human hippocampus,
combined with in vitro and in vivo data, revealed SESN3-
dependent regulation of epileptogenic IL-1b3 and TLR-signalling
genes1. The upstream genetic control of the proconvulsant
transcriptional programme by SESN3 in human TLE-
hippocampus suggested a role for this gene in modulating
seizures. To test the potential functional role of SESN3 in vivo, we
used an experimental model of acute epileptic seizures34,37 and
found that knockdown of Sesn3 attenuated chemical convulsant-
induced locomotor activity and c-fos expression, as well as
modulating Module-1 gene expression (Fig. 5). Our in vitro data
in macrophages, BV2 microglial cells and primary neurons
showed that SESN3 is a positive regulator of proinﬂammatory
molecules (Fig. 4), including IL-1b and TNF-a, major mediators
of inﬂammation, which are capable of inducing changes in
neuronal excitability50. The ﬁnding of reduced severity of
PTZ-induced seizures upon knockdown of Sesn3 in the
zebraﬁsh model is consistent with previous studies in rodents
describing the effects of proinﬂammatory cytokines on seizures.
In the context of pre-existing brain inﬂammation, antibody-
mediated antagonism of TNF-a function inhibited susceptibility
to PTZ-induced seizures in rats51, whereas administration of
exogenous TNF-a increased susceptibility to PTZ-induced
seizures52. Our ﬁndings in zebraﬁsh are therefore in keeping
with a role for SESN3 in regulating proinﬂammatory cytokines
and their downstream effect on CNS excitability and seizure
susceptibility.
Taken together, our data provide the ﬁrst evidence of a
function for SESN3 in regulating proconvulsant agents (for
example, TNF-a, IL-1 and TLR-signalling genes) in human
epileptic hippocampus, and suggest SESN3 as a new potential
target for modulating brain inﬂammation3,44 and CNS
excitability53. Our systems genetics approach builds on and
extends previous methods correlating individual genetic variation
with disease susceptibility by identifying disease-associated gene
networks, pathophysiological pathways and their upstream
genetic regulators in human brain. More generally, the systems
genetics framework described here can be employed to identify
genes and regulatory networks across diverse neuropsychiatric
disorders where genetic factors can perturb underlying molecular
pathways in the brain.
Methods
Gene expression proﬁling in the human hippocampus. All 129 patients
considered in this study had mesial TLE and all tissue samples were from
indistinguishable hippocampal tissue portions. Sample preparation and microarray
analysis of human hippocampi are detailed in Supplementary Methods. Expression
data were analysed using Illumina’s GenomeStudio Gene Expression Module and
normalized by quantile normalization with background subtraction. Microarray
probes were annotated using either the Human HT-12 v3 annotation ﬁle or
Ensembl (release 72). All patients gave informed consent for use of their tissue and
all procedures were conducted in accordance with the Declaration of Helsinki and
approved by the Ethics Committee of the University of Bonn Medical Center.
Gene co-expression network analysis. Gene co-expression networks were
reconstructed using GGMs, which use partial correlations to infer co-expression
relationships between any microarray probe pair in the data set, removing the
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effect of other probes23. We used the empirical Bayes local FDR statistics54
to extract signiﬁcant partial correlations (Supplementary Fig. 13), and which
identiﬁed a large set of 2,124 inter-connected nodes belonging to the same
connected component (TLE-network, Supplementary Data 2). Network extraction
and identiﬁcation of transcriptional modules are described in the Supplementary
Methods.
Mapping the genetic control of networks. We used Bayesian variable selection
models18,29 to identify the genetic control points (regulatory ‘hotspots’) of
transcriptional modules in the TLE patient cohort. First, we combined PC
analysis55 with multivariate regression approaches to prioritize genome-wide
genomic regions associated with the module expression. We then analysed all genes
of the module with all SNPs in the regulatory region using the hierarchical
evolutionary stochastic search algorithm18, where the module genes’ expression are
jointly considered. Further details are reported in Supplementary Methods.
Genetic association of the TLE-network with epilepsy. To test if TLE-network
genes are likely to be causally involved in the disease process, we assessed whether
network genes are enriched for SNP variants associated to focal epilepsy by
GWAS6,25. Full details on the GWAS of focal epilepsy are reported in
Supplementary Methods. Brieﬂy, in the GWAS-enrichment analysis each gene of
the TLE-network was assigned a GWAS signiﬁcance value consisting of the
smallest P-value of all SNPs mapped to it. We used the hypergeometric distribution
test to assess whether SNPs close to (o100 kb from) any network gene were more
likely to associate with epilepsy by GWAS than SNPs close to genes not in the
TLE-network. Empirical GWAS-enrichment P-values were generated by 1,000,000
randomly selected gene-sets and are reported in Supplementary Table 2 (see
Supplementary Methods for additional details).
RNA-Seq analysis in the mouse hippocampus. RNA-Seq analysis in whole
hippocampus from 100 epileptic (pilocarpine model)27 and 100 control naı¨ve mice
(NMRI) is detailed in Supplementary Methods. Brieﬂy, raw reads were mapped to
the reference mouse genome (mm10) using TopHat version 2.0.8 (ref. 56) and read
counts per gene were normalized across all samples using the ‘trimmed mean of
M-value’ approach57. Differential expression analysis was performed using the
edgeR57 and a threshold of 5% FDR was used to identify signiﬁcant gene expression
changes. Experimental animals were used only once for each study. All
experimental procedures complied with the guidelines of the European Union
Directive 2010/63/EU. A local ethical committee approved the experimental
protocol.
In vitro studies. Details on all cell cultures used in these studies are reported
in Supplementary Methods. SiRNA knockdown experiments were performed
in murine BMDMs and BV2 microglia cell lines using a mouse Sesn3
ON-TARGETplus SMARTpool siRNA (100 nM, ThermoFisher Scientiﬁc) and
Dharmafect 1 (ThermoFisher Scientiﬁc) as transfection reagent, according to
the manufacturer’s recommendations. For LPS stimulation experiments, the
transfected cells were washed twice in DMEM and stimulated with LPS (Sigma,
100 ngml 1) for an hour. For overexpression experiments, a third-generation LV
was used to transduce murine primary hippocampal neuronal culture. Additional
information and details on Sesn3 siRNA target sequences, the real-time quantita-
tive PCR for Module-1 genes and primer sequences are given in Supplementary
Methods and Supplementary Table 4. The relative expression levels normalized to
Beta-actin (or Gapdh as indicated) gene expression were then determined by the
2DDCt method.
In vivo studies. To study the function of sestrin 3 in response to PTZ-induced
seizures, two different morpholinos were designed to block the normal splicing
of the zebraﬁsh Sesn3 primary transcript (see Supplementary Fig. 12 and
Supplementary Methods). Embryos that were to be analysed by whole-mount
in situ hybridization were ﬁrst treated with 1-phenyl-2 thiourea at 23 h post
fertilization (h.p.f.) to inhibit melanogenesis. At 3 d.p.f., larvae were treated for 1 h
with 20mM PTZ or left untreated, and all larvae were then ﬁxed with paraf-
ormaldehyde immediately after the treatment period. RNA in situ hybridization
analysis was carried out using a c-fos digoxigenin-labelled probe, which was pre-
pared as recommended by the manufacturer of the in situ hybridization reagents
(Roche). Whole-mount in situ hybridization was performed using standard
procedures58. Analysis of zebraﬁsh locomotor activity was carried out using the
Viewpoint Zebrabox system (Viewpoint) as previously reported in ref. 34. Brieﬂy,
3 d.p.f. larvae were incubated in E3 medium with or without 20mM PTZ in
microtitre plates, with one larva per well, and larval movements were recorded with
the Viewpoint Zebrabox over a recording period of 60min, using a light cycle of
2min: 100% light; 2min: 0% light. The distance swam by each larva was measured
for every 10-min period during the recording period, and the cumulative distance
swam over the recording period was calculated. Rescue experiments were
performed by co-injection of synthetic sesn3 RNA into one-cell stage AB wild-type
zebraﬁsh embryos alone (2 nl of 0.3 ng nl 1 sesn3 mRNA) or in combination with
Sesn3 morpholinos. Additional details, including the quantitative PCR analyses of
c-fos and Module-1 genes, primer sequences are reported in Supplementary
Methods. All experimental procedures involving zebraﬁsh were performed in
compliance with the UK Animal (Scientiﬁc Procedures) Act and approved by the
University of Shefﬁeld Animal Welfare Ethical Review Board.
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